Back to top
more

Aurora Cannabis (ACB)

(Delayed Data from NSDQ)

$6.25 USD

6.25
2,590,496

+0.50 (8.70%)

Updated Jul 22, 2024 03:59 PM ET

After-Market: $6.27 +0.02 (0.32%) 6:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Aurora Cannabis Inc. (ACB) Surpasses Q4 Earnings Estimates

Aurora Cannabis (ACB) delivered earnings and revenue surprises of 161.11% and 2.54%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

High Tide Inc. (HITI) Reports Break-Even Earnings for Q2

High Tide (HITI) delivered earnings and revenue surprises of 100% and 2.73%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

SolGel Technologies (SLGL) delivered earnings and revenue surprises of -53.33% and 64.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Canopy Growth (CGC): Can Its 11.0% Jump Turn into More Strength?

Canopy Growth (CGC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 60% and 7.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Aurora Cannabis (ACB) Moves 46.0% Higher: Will This Strength Last?

Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?

Here is how Adverum Biotechnologies (ADVM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.

Aurora Cannabis Inc. (ACB) Suffers a Larger Drop Than the General Market: Key Insights

Aurora Cannabis Inc. (ACB) concluded the recent trading session at $6.46, signifying a -1.15% move from its prior day's close.

Aurora Cannabis Inc. (ACB) Reports Q3 Loss, Tops Revenue Estimates

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -100% and 16.10%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

Here is how Adicet Bio, Inc. (ACET) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.

Quanterix Corporation (QTRX) Moves 7.2% Higher: Will This Strength Last?

Quanterix Corporation (QTRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Aurora Cannabis Inc. (ACB) Reports Q4 Loss, Tops Revenue Estimates

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 50% and 19.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

QuidelOrtho (QDEL) Beats Q2 Earnings and Revenue Estimates

QuidelOrtho (QDEL) delivered earnings and revenue surprises of 4% and 7.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Beat Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of 15.63% and 3.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Aurora Cannabis Inc. (ACB) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Aurora Cannabis Inc. (ACB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

OraSure Technologies (OSUR) Q1 Earnings and Revenues Beat Estimates

OraSure (OSUR) delivered earnings and revenue surprises of 131.25% and 21.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

InMode (INMD) Q1 Earnings and Revenues Top Estimates

InMode (INMD) delivered earnings and revenue surprises of 4% and 0.26%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Aurora Cannabis Inc. (ACB) Reports Q2 Loss, Tops Revenue Estimates

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -100% and 19.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Aurora Cannabis (ACB) Outperforming Other Medical Stocks This Year?

Here is how Aurora Cannabis Inc. (ACB) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Aurora Cannabis (ACB) This Year?

Here is how Aurora Cannabis Inc. (ACB) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Aurora Cannabis Inc. (ACB) Reports Q1 Loss, Misses Revenue Estimates

Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of 11.11% and 2.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?

Continued strength in Aurora Cannabis' (ACB) domestic adult recreational segment is expected to have driven Q1 sales.

Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 18.37% and 83.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Q1 Earnings Match Estimates

ResMed (RMD) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?